围术期镁预防手术患者寒战:系统评价与Meta分析
该系统评价与Meta分析纳入64项随机对照试验共4303例手术患者,评估围术期镁预防寒战的效果。镁组寒战总发生率为9.9%,对照组为23.0%(RR 0.42,95%CI 0.33-0.52)。亚组分析显示静脉、硬膜外和鞘内给药均降低寒战发生率,试验序贯分析提示静脉镁有效且无需更多试验证实。
要点
- 围术期静脉给予镁可有效降低手术患者寒战发生率。
- 静脉、硬膜外和鞘内给药途径均显示寒战发生率降低。
- 未报告不良事件增加,试验序贯分析支持静脉镁的获益。
核心结论
- 围术期静脉给予镁有效减少寒战,试验序贯分析提示无需更多试验证实该效果。
研究设计与样本
- 系统评价与Meta分析,检索PubMed、EMBASE、Web of Science、Cochrane Central Register of Controlled Trials及2个注册网站,纳入比较镁与安慰剂或不治疗的随机临床试验。
- 共纳入64项试验、4303例患者(镁组2300例,对照组2003例)。
- 主要结局为寒战发生率,采用随机效应模型合并风险比(RR)及95%CI,并进行亚组分析和试验序贯分析(Ⅰ类错误风险5%,把握度90%)。
- 采用GRADE方法评估证据质量,并评估不良事件。
主要发现
- 镁组寒战总发生率为9.9%,对照组为23.0%(RR 0.42;95%CI 0.33-0.52)。
- 亚组分析显示静脉给药降低寒战发生率(RR 0.29;95%CI 0.29-0.54;GRADE中等)。
- 硬膜外给药降低寒战发生率(RR 0.24;95%CI 0.13-0.43;GRADE低)。
- 鞘内给药降低寒战发生率(RR 0.64;95%CI 0.43-0.96;GRADE中等)。
- 仅低偏倚风险试验纳入试验序贯分析,静脉镁的Z累积曲线跨越获益监测边界(仅达目标样本量34.9%),硬膜外或鞘内给药的Z累积曲线未跨越获益监测边界。
关键数值与推荐
- 静脉镁降低寒战发生率:RR 0.29(95%CI 0.29-0.54),GRADE中等。
- 硬膜外镁降低寒战发生率:RR 0.24(95%CI 0.13-0.43),GRADE低。
- 鞘内镁降低寒战发生率:RR 0.64(95%CI 0.43-0.96),GRADE中等。
- 总体寒战发生率镁组9.9% vs 对照组23.0%,RR 0.42(95%CI 0.33-0.52)。
临床怎么用
- 围术期可考虑静脉给予镁以预防手术患者寒战。
- 硬膜外或鞘内给药也可能降低寒战,但证据质量较低且试验序贯分析未确认获益。
局限性
- 硬膜外给药的证据质量等级为低。
- 硬膜外或鞘内给药的试验序贯分析未跨越获益监测边界。
- 仅低偏倚风险试验纳入试验序贯分析,静脉镁分析仅达目标样本量的34.9%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clinical trials regarding the antishivering effect of perioperative magnesium have produced inconsistent results. We conducted a systematic review and meta-analysis with Trial Sequential Analysis to evaluate the effect of perioperative magnesium on prevention of shivering. METHODS: We searched PubMed, EMBASE, Web of Science, Cochrane Central Register of Controlled Trials, and 2 registry sites for randomized clinical trials that compared the administration of magnesium to a placebo or no treatment in patients undergoing surgeries. The primary outcome of this meta-analysis was the incidence of shivering. The incidence of shivering was combined as a risk ratio with 95% CI using a random-effect model. The effect of the route of administration was evaluated in a subgroup analysis, and Trial Sequential Analysis with a risk of type 1 error of 5% and power of 90% was performed. The quality of each included trial was evaluated, and the quality of evidence was assessed using the Grading of Recommendation Assessment, Development, and Evaluation approach. We also assessed adverse events. RESULTS: Sixty-four trials and 4303 patients (2300 and 2003 patients in magnesium and control groups, respectively) were included. The overall incidence of shivering was 9.9% in the magnesium group and 23.0% in the control group (risk ratio, 0.42; 95% CI, 0.33-0.52). Subgroup analysis revealed that the incidence of shivering was lower with IV (risk ratio, 0.29; 95% CI, 0.29-0.54; Grading of Recommendation Assessment, Development, and Evaluation, moderate), epidural (risk ratio, 0.24; 95% CI, 0.13-0.43; Grading of Recommendation Assessment, Development, and Evaluation, low), and intrathecal administration (risk ratio, 0.64; 95% CI, 0.43-0.96; Grading of Recommendation Assessment, Development, and Evaluation, moderate). Only trials with low risk of bias were included for Trial Sequential Analysis. The Z-cumulative curve for IV magnesium crossed the Trial Sequential Analysis monitoring boundary for benefit even though only 34.9% of the target sample size had been reached. The Z-cumulative curve for epidural or intrathecal administration did not cross the Trial Sequential Analysis monitoring boundary for benefit. No increase in adverse events was reported. CONCLUSIONS: Perioperative IV administration of magnesium effectively reduced shivering and Trial Sequential Analysis suggested that no more trials are required to confirm that IV magnesium effectively reduces shivering.
引用
- Kawakami H, Nakajima D, Mihara T, et al. Effectiveness of Magnesium in Preventing Shivering in Surgical Patients: A Systematic Review and Meta-analysis. Anesth Analg. 2019. PMID: 31425208. doi:10.1213/ANE.0000000000004024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。